(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT04910685 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

534

Enrollment

INDUSTRY

Sponsor class

Conditions

Indolent Systemic Mastocytosis
Smoldering Systemic Mastocytosis

Interventions

DRUG: Elenestinib
DRUG: Placebo

Sponsor

Blueprint Medicines Corporation